focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday broker round-up UPDATE

Thu, 22nd Aug 2013 07:25

Aggreko: RBC Capital reduces target price from 1850p to 1680p, while its neutral rating remains unchanged.Aviva: JP Morgan raises target price from 393p to 436p and retains an overweight rating.BHP Billiton: Canaccord Genuity takes target price from 1950p to 2050p maintaining a hold recommendation.Cairn Energy: RBC Capital moves target price from 440p to 450p and reiterates its outperform rating.Cropper (James): Westhouse Securities ups target price from 300p to 350p, while downgrading to add.Faroe Petroleum: Liberum Capital lowers target price from 188p to 183p, while leaving its buy recommendation unchanged.Ferrexpo: Cantor Fitzgerald reduces target price from 373p to 290p, but stays with its buy recommendation.Glencore Xstrata: JP Morgan cuts target price from 410p to 390p retaining its overweight rating.Hikma Pharmaceuticals: Jefferies ups target price from 1200p to 1250p and keeps a buy recommendation.Hochschild Mining: Westhouse Securities increases target price from 150p to 200p and reiterates a neutral rating. JP Morgan moves target price from 75p to 80p, while keeping an underweight rating. Citi shifts target price from 133p to 132p and maintains its sell recommendation. RBC Capital ups target price from 220p to 260p and stays with its neutral rating.IMI: Investec places both its target price (prev.: 1350p) and its hold recommendation under review.Intertek Group: Credit Suisse reduces target price from 3850p to 3600p, while retaining an outperform rating.IP Group: Numis lowers target price from 129p to 124p, while its hold recommendation remains unchanged.John Wood Group: JP Morgan cuts target price from 963p to 951p and stays with its neutral rating. Liberum Capital reduces target price from 892p to 874p.Legal & General Group: Morgan Stanley moves target price from 184p to 192p and maintains an equal-weight rating.Lloyds Banking Group: Jefferies shifts target price from 65p to 69p reiterating a hold recommendation.Sportech: Investec lowers target price from 110p to 105p and leaves its buy recommendation unaltered.Stagecoach Group: Deutsche Bank raises target price from 330p to 350p staying with its buy recommendation.Summit Corporation: N+1 Singer shifts target price from 8.80p to 10.70p keeping its buy recommendation.Vitec Group: Investec increases target price from 740 to 810p and retains a buy recommendation.Wolseley: UBS upgrades from neutral to buy with a target price of 3500p.
More News
15 Dec 2016 12:38

Summit Therapeutics widens loss as drug development continues

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its financial results for the third quarter to 31 October on Thursday. The AIM-traded firm had cash and cash equivalents at period end of £34.6m compared to £16.3m on 31 January. Its loss for the nine months was £1

Read more
16 Nov 2016 12:28

Summit Therapeutics enrols first US patients in ezutromid trial for DMD

(ShareCast News) - AIM-listed drug discovery and development company Summit Therapeutics has enrolled its first patients in phase II proof of concept trials in the US of ezutromid in patients with Duchenne muscular dystrophy. Summit said enrolment and dosing of patients into Phase Out DMD in the UK

Read more
6 Oct 2016 14:28

Summit Therapeutics shares plummet despite positive progress

(ShareCast News) - Drug discovery and development company Summit Therapeutics presented preclinical data at the 21st International Congress of the World Muscle Society in Granada, Spain on Thursday, including further findings from its programme to develop tools to measure biomarkers of muscle health

Read more
4 Oct 2016 11:52

BUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal

** Shares in drug developer Summit Therapeutics up 58 pct after teams up with US drug co Sarepta Therapeutics to develop and market DMD drug in Europe ** Stock poised for its best day since April 2009 ** Co gets $40 mln upfront payment, could receive up to $522 million in milestone p

Read more
9 Aug 2016 11:51

Summit Therapeutics Sees Positive Phase I Trial Results For Ezutromid

Read more
21 Jun 2016 06:46

Summit Therapeutics Shows Further Positive Trial Data For Ridinilazole

Read more
17 Jun 2016 11:21

Summit Therapeutics Enrols First Patient In Phase II Ezutromid Trial

Read more
2 Jun 2016 14:30

Cash reduced, losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its first quarter results on Thursday, with cash reduced and losses widening. The AIM-traded firm, which is advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), had cash and ca

Read more
10 May 2016 16:46

Losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics reported an increase in cash and activities in its full-year results on Tuesday, though its losses widened as it carried its projects towards commercialisation. The AIM-traded firm had cash and cash equivalents of £16.3m o

Read more
10 May 2016 11:20

Summit Therapeutics Posts Widened Loss As It Progresses Programmes

Read more
28 Apr 2016 11:11

Summit Therapeutics Gets Further US Patent For Antibiotic Ridinlazole

Read more
26 Apr 2016 11:16

Summit Therapeutics Gets Clearance To Expand Ezutromid Trial To US

Read more
30 Mar 2016 12:48

Summit reports positive results from Duchenne muscular dystrophy treatment

(ShareCast News) - Summit Therapeutics reported positive interim findings on Wednesday, from a recent Phase 1 trial of a new oral formulation of its SMT C1100 therapy for Duchenne muscular dystrophy. The AIM-traded drug discovery and development company focuses on advancing therapies for Duchenne mu

Read more
30 Mar 2016 11:06

Summit Therapeutics Gets Positive Interim SMT C1100 Test Results

Read more
7 Mar 2016 12:43

Summit Therapeutics Sees Further Positive Data For Ridinilazole

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.